Medications Associated with Hair Loss
Chemotherapy agents, particularly taxanes (docetaxel, paclitaxel) and anthracyclines (doxorubicin), cause the most severe and frequent alopecia, with rates exceeding 90% in combination regimens, while endocrine therapies (aromatase inhibitors, tamoxifen), antiseizure medications (valproate, lamotrigine, carbamazepine), biologics (adalimumab, infliximab), and anticoagulants (heparin, warfarin, enoxaparin) represent other major drug classes associated with hair loss.
Anticancer Agents
Chemotherapy-Induced Alopecia (CIA)
Cytotoxic chemotherapy causes the most dramatic hair loss through p53-mediated apoptosis of hair matrix keratinocytes and stem cells 1:
- Highest risk agents: Taxanes (docetaxel/paclitaxel), anthracyclines (doxorubicin), and cyclophosphamide combinations cause grade 2 alopecia (>50% hair loss) in 48-100% of patients 1, 2
- Timing: Hair loss begins 1-3 weeks after initiation, with regrowth starting 2-3 months post-completion at approximately 1 cm/month 1
- Persistent alopecia: Contrary to historical teaching, persistent CIA (pCIA) beyond 6 months occurs in up to 67% of doxorubicin-treated patients and 50% of docetaxel combinations—far higher than the previously cited 1-15% 3, 2
- Other agents: Capecitabine, erlotinib, imatinib, and bortezomib also cause alopecia with strong evidence 4
Endocrine Therapy-Induced Alopecia (EIA)
Hormonal agents cause a distinct pattern of hair loss 1:
- Aromatase inhibitors (AIs): Cause grade 1 alopecia in 4.4-22.4% of patients, with hair thinning reported in 31.8% 1
- Tamoxifen: Shows higher reported incidence (25%), possibly due to younger patient population being more aware of changes 1
- Pattern: Crown thinning with frontal/bitemporal recession, developing 6-18 months after initiation
- Impact: Up to 8% of patients discontinue AIs specifically due to alopecia 1
Biologics
Tumor necrosis factor inhibitors have strong evidence for alopecia 4:
- Adalimumab and infliximab are associated with hair loss in high-quality studies
Antiseizure Medications
Antiseizure drugs represent a major non-oncologic cause of alopecia 5:
- Most commonly implicated: Valproate (983 reported cases), lamotrigine (355 cases), carbamazepine (225 cases)
- Other agents: Levetiracetam, topiramate, lacosamide, gabapentin, phenytoin, pregabalin
- Mechanism: Predominantly telogen effluvium causing diffuse, non-scarring hair loss
- Reversibility: Hair loss is characteristically reversible with dose adjustment or discontinuation 5
Anticoagulants
Both traditional and newer anticoagulants cause alopecia through telogen effluvium 6:
- Heparin and enoxaparin: Well-documented association with strong evidence 4
- Warfarin: Established cause of hair loss
- Direct oral anticoagulants (DOACs): 405 reports in WHO pharmacovigilance database, with 4.4 per 100 patient-years incidence for rivaroxaban and dabigatran 6
- Shared mechanism: Timing and presentation suggest anticoagulant activity itself triggers telogen effluvium, meaning DOACs do NOT provide a safe alternative for patients with traditional anticoagulant-induced alopecia 6
Other Medication Classes
Additional agents with strong evidence 4, 7:
- Immunosuppressants: Tacrolimus, interferon β-1α
- Corticosteroids: Budesonide (systemic effects)
- Vaccines: Zoster vaccine
- Antifungals: Various agents through metabolic disruption 7
Clinical Approach
Differential Diagnosis
When evaluating medication-associated alopecia, rule out 1:
- Thyroid dysfunction (TSH, free T4)
- Iron deficiency (ferritin)
- Vitamin D and zinc deficiency
- Female-pattern hair loss
- Alopecia areata
- Inflammatory/scarring alopecia
Pattern Recognition
- Chemotherapy: Diffuse grade 2 alopecia affecting entire scalp, eyebrows, eyelashes within 1-3 weeks
- Endocrine therapy: Crown thinning with frontal recession developing over 6-18 months
- Antiseizure medications: Diffuse telogen effluvium, reversible with dose adjustment
- Anticoagulants: Telogen effluvium pattern
Critical Pitfalls
Underestimating persistence: Persistent CIA is far more common than historically reported—counsel patients that permanent hair changes may occur in up to 50-67% with certain regimens 3, 2
DOAC misconception: Do not switch patients from heparin/warfarin to DOACs expecting to avoid alopecia—the mechanism appears related to anticoagulation itself 6
Premature reassurance: The psychosocial impact of even grade 1 alopecia is significant and warrants attention, not dismissal 1
Missing baseline findings: Up to 30% of patients show pre-existing miniaturization before chemotherapy, predicting poor regrowth prognosis—trichoscopy before treatment is crucial 3